-
Adjuvant trastuzumab in HER2-positive breast cancerSlamon, Dennis ...Background: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-basedregimens has been associated with cardiac ... toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. Methods: We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followedby docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. Results: At amedian follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. Conclusions: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. (Abstract truncated at 2000 characters)Source: The New England journal of medicine. - ISSN 0028-4793 (Vol. 365, issue 14, 2011, str. 1273-1283)Type of material - article, component partPublish date - 2011Language - englishCOBISS.SI-ID - 29394393
Author
Slamon, Dennis |
Eiermann, Wolfgang |
Robert, Nicolas |
Pienkowski, Tadeusz |
Martin, Miguel |
Press, Michael |
Mackey, John |
Glaspy, John |
Chan, Arlene |
Pawlicki, Marek
Other authors
Matos, Erika |
Čufer, Tanja, 1955- |
Takač, Iztok
Topics
Breast Neoplasms |
Drug Therapy |
Antibodies, Monoclonal |
Proto-Oncogene Proteins C-Erbb-2 |
Anthracyclines |
Stroke Volume |
Heart Failure, Congestive |
Disease-Free Survival |
Survival Analysis |
Follow-Up Studies |
Antraciklini |
Protitelesa monoklonska |
Utripni volumen |
Dojka, novotvorbe |
Preživetje, analiza |
Brez bolezni, preživetje |
Srce, odpoved kongestivna |
Sledilne študije
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Slamon, Dennis | ![]() |
Eiermann, Wolfgang | ![]() |
Robert, Nicolas | ![]() |
Pienkowski, Tadeusz | ![]() |
Martin, Miguel | ![]() |
Press, Michael | ![]() |
Mackey, John | ![]() |
Glaspy, John | ![]() |
Chan, Arlene | ![]() |
Pawlicki, Marek | ![]() |
Matos, Erika | 20055 |
Čufer, Tanja, 1955- | 12179 |
Takač, Iztok | 01324 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.